PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News:
NANOBIOTIX SA (Euronext : NANO – ISIN : FR0011341205) announced today
that it plans to conduct a registered public offering of its ordinary
shares, including in the form of American Depositary Shares (ADSs) in
the United States, and has confidentially submitted a draft registration
statement on Form F-1 to the U.S. Securities and Exchange Commission.
The timing, number of new ordinary shares and ADSs to be issued, the
price of such shares and ADSs, and the other terms of the proposed
offering have not yet been determined.
This announcement is being made pursuant to and in accordance with Rule
135 under the Securities Act of 1933. This press release does not, and
is not intended to, constitute an offer to sell or the solicitation of
an offer to buy securities, and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of that jurisdiction.
Incorporated in 2003, Nanobiotix is a late clinical-stage nanomedicine
company pioneering new approaches to significantly change patient
outcomes by bringing nanophysics to the heart of the cell.
Nanobiotix is listed on the regulated market of Euronext in Paris
(Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The
Company’s headquarters are based in Paris, France, with a U.S. affiliate
in Cambridge, MA, and European affiliates in Spain and Germany.
France – Springbok Consultants
+33 (0)6 71 58 00 34
United States – RooneyPartners